MiMedx offers the largest selection of placental-based allografts to meet the needs of patients and providers.

Learn more about our recently published multicenter diabetic foot ulcer randomized controlled trials on EpiFix® and EpiCord®:

Subjects treated with EpiFix were more than twice as likely to heal completely within 12 weeks as those not receiving EpiFix ¹.
EpiCord patients were significantly more likely to completely heal compared to control ².

1. Bianchi C, Cazzell S, Vayser D, Reyzelman AM, Dosluoglu H, Tovmassian G; EpiFix Study Group. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers. Int Wound J. 2018 Feb; 15(1):114-122.

2. Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J. 2019 June; 16:122-130.

DA104.001

Discover

the MiMedx

Advantage